ChartMill · Oct 30, 2026
Protagonist Therapeutics (NASDAQ:PTGX) Eyes Breakout as High Growth Momentum Builds
PTGX blends strong technicals (9) and high growth momentum (6) with a Setup Rating of 7, nearing a breakout despite clinical-stage risks.
PT
NASDAQ · PTGX
Protagonist Therapeutics, Inc.
Healthcare · Biotechnology
$140.24
Up+$0.88 (+0.62%)
Updated Nov 4, 2026, 4:44 PM
SID Score
5.1/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 5.77B
- P/E ratio
- 128.14
- Dividend yield
- 0.00%
- 52-week range
- $90.58 – $160.81
- Volume
- 675.16K
- Avg. volume
- 1.18M
Price performance · PTGX
PTGX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
PTGX closed at $140.24 after 21 trading sessions, up 1.12% for the selected period.
- Last close
- $140.24
- Period change
- +1.12%
- Period low
- $128.75
- Period high
- $144.88
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $140.73 | $144.265 | $139.91 | $140.24 | 675.16K |
| Nov 2, 2026 | $145.74 | $146.005 | $139.35 | $139.37 | 486.66K |
| Oct 30, 2026 | $144.34 | $146.00 | $142.54 | $144.85 | 322.57K |
| Oct 29, 2026 | $144.03 | $146.44 | $142.87 | $144.34 | 325.56K |
| Oct 28, 2026 | $139.35 | $143.26 | $138.29 | $142.14 | 318.46K |
| Oct 27, 2026 | $140.08 | $142.37 | $137.91 | $141.12 | 865.93K |
| Oct 26, 2026 | $139.24 | $142.00 | $137.2981 | $140.32 | 823.28K |
| Oct 23, 2026 | $136.89 | $139.5229 | $135.00 | $138.43 | 409.36K |
| Oct 22, 2026 | $137.49 | $141.375 | $136.07 | $139.53 | 404.39K |
| Oct 21, 2026 | $139.71 | $141.85 | $137.9625 | $138.08 | 990.17K |
| Oct 20, 2026 | $135.87 | $140.82 | $134.325 | $137.99 | 774.48K |
| Oct 19, 2026 | $130.09 | $134.97 | $128.01 | $134.44 | 654.18K |
| Oct 16, 2026 | $136.16 | $136.555 | $126.39 | $128.75 | 886.81K |
| Oct 15, 2026 | $136.72 | $139.11 | $136.025 | $136.55 | 707.74K |
| Oct 14, 2026 | $138.06 | $141.13 | $135.62 | $136.28 | 679.1K |
| Oct 13, 2026 | $146.00 | $146.00 | $137.81 | $138.49 | 1.03M |
| Oct 12, 2026 | $145.83 | $152.185 | $143.69 | $144.88 | 898.52K |
| Oct 9, 2026 | $139.91 | $146.30 | $138.95 | $143.73 | 763.1K |
| Oct 8, 2026 | $139.57 | $142.18 | $137.99 | $139.91 | 1M |
| Oct 7, 2026 | $137.34 | $144.10 | $137.25 | $140.92 | 927.27K |
| Oct 6, 2026 | $140.34 | $141.00 | $136.09 | $138.69 | 635.72K |
Latest PTGX news
The latest Smart Investors Daily articles mentioning PTGX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PTGX research
Overview
Company profile and research snapshot.
Company profile
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $90.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | TD Cowen | Buy | — |
| Oct 12, 2026 | UBS | Buy | — |
| Sep 1, 2026 | BMO Capital | Outperform | — |
| Sep 1, 2026 | Barclays | Overweight | — |
| Aug 31, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 29, 2026
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 28, 2026
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Yahoo · Oct 27, 2026
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026
NEWARK, CA / ACCESS Newswire / October 27, 2026 / (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that senior management will participate in four investment bank conferences taking place in November 2026.8th Annual Wolfe Research Healthcare Conference Format: Fireside Chat and 1x1 meetings Date: Tuesday, November 10, 2026 Time: 1:20 - 1:50 p.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
